Last reviewed · How we verify
Levofloxacin intravenous solution
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.
At a glance
| Generic name | Levofloxacin intravenous solution |
|---|---|
| Also known as | Cravit intravenous solution |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a fluoroquinolone antibiotic, levofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This leads to disruption of bacterial DNA synthesis, cell death, and bactericidal activity against a broad spectrum of gram-positive and gram-negative organisms.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute bacterial exacerbation of chronic bronchitis
- Complicated urinary tract infections
- Uncomplicated urinary tract infections
- Acute pyelonephritis
- Skin and soft tissue infections
- Intra-abdominal infections
- Bacterial prostatitis
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Headache
- Dizziness
- Tendinitis/tendon rupture
- QT prolongation
- Photosensitivity
- Peripheral neuropathy
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy (NA)
- Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia (PHASE3)
- Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection (PHASE4)
- Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution (PHASE4)
- Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis (NA)
- Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levofloxacin intravenous solution CI brief — competitive landscape report
- Levofloxacin intravenous solution updates RSS · CI watch RSS
- Mackay Memorial Hospital portfolio CI